Eisai Slams DEA Over Delay In Scheduling Seizure Med

Law360, New York (August 19, 2013, 7:46 PM EDT) -- A U.S. unit of Japanese pharmaceutical firm Eisai Co. Ltd. launched an appeal in the D.C. Circuit on Monday to order the U.S. Drug Enforcement Administration to schedule its epilepsy drug Fycompa, citing the agency’s “egregious” delay to do so even though U.S. regulators have approved the drug.

Eisai Inc. argued in a petition to the U.S. Court of Appeals for the District of Columbia Circuit that the DEA’s delay in scheduling — a step required under the Controlled Substances Act to determine what category a drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.